Sign inStart free

Health Care · Pharmaceutical Preparations

ARCT Arcturus Therapeutics Holdings Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 176822464 filings
Russell 2000
Follow ARCT for alertsAsk AI about ARCT

ARCT at a glance

Arcturus Therapeutics Holdings Inc. (ARCT, SEC CIK 1768224) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 23, 2026 and Form 4 insider filings as recently as June 15, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Arcturus Therapeutics Holdings Inc. (ARCT) reported revenue of $82.0 million (down 46.1% from FY2024) and a net loss of $65.8 million. Diluted EPS was -$2.40.
  • As of June 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Arcturus Therapeutics Holdings Inc. (ARCT) shares worth $81.5 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$82.0M
−46.1% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
27 funds
$81.5M · +2 vs prior quarter
Latest 8-K
Sep 23, 2026
Item 7.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Jun 30, 2026

Management Discussion & Analysis

  • Revenue $3.0M, down 90% YoY from $28.3M, driven by lower CSL collaboration revenue
  • Operating expenses $28.5M, down 29% YoY from $39.9M
  • LUNAR-CF R&D $2.6M, down 44% YoY; LUNAR-OTC $1.9M, down 36%
  • Cash $191.5M at June 30; six-month operating cash outflow $39.4M vs $40.9M
  • Outlook: losses expected to continue; cash sufficient through at least next twelve months; additional capital anticipated

AI summary of the ARCT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Sep 23, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Boilerplate incorporation language for the Company’s Regulation FD disclosure
  • No substantive operating, financial, or investor-impacting information in the provided excerpt

Item EX-99.1: Item EX-99.1

  • ARCT-810 Phase 2 interim data showed favorable safety and improved ammonia and glutamine biomarkers, supporting continued clinical development
  • LUNAR 2.0 delivered 40-fold higher hEPO expression and 38-fold higher hOTC potency than comparators in NHP studies
Filed Aug 25, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Reg FD section contains only an incorporation-exclusion clause
  • No substantive company disclosure or investor-actionable information provided
Filed Aug 6, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Filing references an earnings press release, but the provided text contains no operating or financial results
  • Investor focus: pipeline execution for ARCT-032 and ARCT-810, including Phase 2 enrollment and potential Phase 3 timing

Item EX-99.1: Item EX-99.1

  • Q2 revenue $3.0M versus $28.3M, reflecting sharply reduced CSL Seqirus collaboration revenue ahead of termination
  • Net loss widened to $23.8M, or $0.84 per share, versus $9.2M, or $0.34, despite lower R&D spending

AI summaries of ARCT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ARCT

Don't miss the next ARCT filing

  • Alerts as it files. A push when ARCT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ARCT, by share count.
  • Ask anything. An AI agent that reads every ARCT filing and answers with sources.
Follow ARCT for alertsAsk AI about ARCT
Compare plans →

ARCT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Marquet MagdaAJun 5, 2026-
HOLMES EDWARD WAJun 5, 2026-
Marantz Jing L.AJun 5, 2026-
BARLOW JAMES FAJun 5, 2026-
FARRELL PETER CAJun 5, 2026-
Markels JohnAJun 5, 2026-
Slaoui MoncefAJun 5, 2026-
MULROY DENNISAMay 1, 2026-
Insider trades across all companies →Which insider buys matter →

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$166.8M$152.3M$82.0M
Operating Income-$78.2M-$95.7M-$76.3M
Net Income--$80.9M-$65.8M
Op. Margin-46.9%-62.8%-93.0%
Net Margin--53.1%-80.2%
Balance Sheet
Total Assets-$344.1M$271.1M
Equity$278.5M$241.0M$214.0M
ROE--33.6%-30.7%
Per Share
EPS$-1.12$-3.00$-2.40
Cash Flow
Operating CF--$59.7M-$74.3M
CapEx-$648K$230K

Source: XBRL data in Arcturus Therapeutics Holdings Inc. (ARCT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q2 2026

Aggregate ARCT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ARCT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q2 202627$81.5M
Q1 202625$88.6M
Q4 202525$67.4M
Q3 202525$199.7M
Q2 202525$136.2M
Q1 202522$90.6M
Q4 202416$114.8M
Q3 202416$122.9M
Position changes: Q1 2026 → Q2 2026
Top Buyers
Top Sellers
Closed Positions
None this quarter.

Source: 13F-HR filings on SEC EDGAR (aggregated from 181 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ARCT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KSep 23, 2026Analysis-
8-KAug 25, 2026Analysis-
8-KAug 6, 2026Analysis-
10-QAug 6, 2026Analysis
8-KJul 2, 2026Analysis-
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
8-KJun 5, 2026Analysis
8-KMay 7, 2026Analysis
10-QMay 7, 2026Analysis
4May 7, 2026-
10-KMar 3, 2026-
8-KMar 3, 2026Analysis-
4Dec 19, 2025-
4Dec 19, 2025-
4Dec 19, 2025-
4Dec 19, 2025-
8-KDec 15, 2025-
SC 13GNov 14, 2025-
10-QNov 12, 2025Analysis

Related Health Care companies

All Health Care →

ARCT SEC filings: frequently asked questions

Which institutions hold ARCT stock?

As of June 30, 2026, the largest Arcturus Therapeutics Holdings Inc. (ARCT) holders among the 13F filers tracked by SignalX were ARK Investment Management ($19.5 million), BlackRock ($17.6 million), Vanguard Capital Management LLC ($7.5 million), Two Sigma Investments ($7.3 million), Vanguard Portfolio Management LLC ($6.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ARCT's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Arcturus Therapeutics Holdings Inc. (ARCT) reported revenue of $82.0 million (down 46.1% from FY2024) and a net loss of $65.8 million. Diluted EPS was -$2.40. The figures come from the XBRL data in the 10-K.

What did ARCT report in its latest 8-K?

Arcturus Therapeutics Holdings Inc. (ARCT) filed an 8-K on September 23, 2026 reporting Item 7.01 (Regulation FD Disclosure). Boilerplate incorporation language for the Company’s Regulation FD disclosure.

What are the latest ARCT SEC filings?

Arcturus Therapeutics Holdings Inc. (ARCT) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 23, 2026 and a Form 4 insider filing on June 15, 2026.

What is ARCT's SEC CIK number?

Arcturus Therapeutics Holdings Inc. (ARCT)'s SEC Central Index Key (CIK) is 1768224. EDGAR lists every ARCT filing under that number.

Ask anything about ARCT

The research agent reads ARCT's filings, financials, insider trades and 13F holders, then answers with sources.

Start free